Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells.

@article{Zwezdaryk2007ErythropoietinAH,
  title={Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells.},
  author={Kevin J Zwezdaryk and Seth B Coffelt and Yanira G Figueroa and Juliet Liu and Donald G Phinney and Heather L LaMarca and Luisa F Florez and Cindy B Morris and Gary W. Hoyle and Aline B. Scandurro},
  journal={Experimental hematology},
  year={2007},
  volume={35 4},
  pages={640-52}
}
OBJECTIVE The ability of erythropoietin (EPO) to elicit a pro-angiogenic effect on human mesenchymal stem cells (hMSC) was tested. hMSC are currently under study as therapeutic delivery agents that target tumor vessels. Hypoxia favors the differentiation of hMSC towards a pro-angiogenic program. However, the classical angiogenic factors, vascular endothelial growth factor and basic fibroblast growth factor, are not fully capable of restoring this effect. The hypoxia-regulated factor, EPO… CONTINUE READING